Allarity Signs First CLIA Lab Services Contract

Allarity Therapeutics has signed its first revenue-generating contract under its CLIA-certified laboratory services strategy, agreeing to provide development, validation and related services to a European biotechnology company. The work will support the U.S. implementation of the partner’s precision-oncology predictive device; the partner and financial terms were not disclosed. Allarity said successful completion could lead to ongoing commercial testing and additional service revenue. The deal builds on the company’s July 2026 CLIA certification for its laboratory in Hørsholm, Denmark, and its existing gene-expression and Drug Response Predictor services. Allarity said stenoparib’s clinical development remains its top priority.